(RTTNews) - Clinical-stage biopharmaceutical company Codiak BioSciences Inc. (CDAK), on Thursday, announced platform-validating clinical data from Phase 1 trials of exoSTINGTM and exoIL-12 and plans to advance both candidates into Phase 2 trials.
In an open-label Phase 1 trial, exoIL-12 demonstrated a differentiating favorable safety and tolerability profile, with no detectable systemic exposure of IL-12 and no treatment-related adverse events, which has not previously been reported by others with recombinant IL-12.
The company further noted that two patients with cutaneous T cell lymphoma (CTCL) who have been treated each received multiple injections of exoIL-12 and experienced tumor regressions in both injected and non-injected lesions, including a partial response in one patient.
In the open-label Phase 1/2 clinical trial evaluating exoSTING as a single agent in patients with late-stage refractory solid tumors, data across all five dose cohorts showed repeat doses of exoSTING were well-tolerated, demonstrated tumor retention with no systemic exposure of the STING agonist, and in a subset of patients, tumor shrinkage was observed in injected and uninjected lesions.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
